Early Detection of NSCLC Using Stromal Markers in Peripheral Blood
Abstract
A recent screening trial showed that the use of low dose computed tomography (LDCT) resulted in a 20 reduction in lung cancer mortality, however there was a 96 false positive rate associated with LDCT. Thus, there is an immediate clinical need to develop a diagnostic biomarker that would select patients with CT detected nodules for further testing. The ease with which blood can be sampled makes it a logical choice in which to discover diagnostic biomarkers, however the clinical utility of tumor derived proteins, miRNA or circulating tumor cells as blood-based biomarkers has been limited. In this proposal, instead of tumor-derived biomarkers, we will focus on host response to tumor growth. It has been well documented that tumor growth systemically stimulates and mobilizes BM-derived hematopoietic cells to the tumor bed to establish a permissive microenvironment. Preliminary studies in our lab have shown that in lung cancer patients, the circulating myeloid cells are transcriptionally altered and the alteration is tumor dependent.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2016
- Accession Number
- AD1033075
Entities
People
- Dingcheng Gao
Organizations
- Weill Cornell Medicine